Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

v3.5.0.2
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Schedule of Effect of Revision on Financial Statements
   
December 31, 2015
 
   
As previously
             
   
reported
   
Adjustment
   
As revised
 
Deferred revenue
 
$
7,507,176
   
$
2,459,717
   
$
9,966,893
 
Total current liabilities
   
13,368,329
     
2,459,717
     
15,828,046
 
Total liabilities
   
18,782,659
     
2,459,717
     
21,242,376
 
Accumulated deficit
   
(40,890,017
)
   
(2,459,717
)
   
(43,349,734
)
Stockholders’ equity
 
$
22,645,157
   
$
(2,459,717
)
 
$
20,185,440
 

   
Three Months Ended
 
   
September 30, 2015
 
   
As previously
             
   
reported
   
Adjustment
   
As revised
 
Revenues
 
$
9,343,312
   
$
(122,133
)
 
$
9,221,179
 
Impairment expense
   
24,717,157
     
2,027,092
     
26,744,249
 
Loss from operations
   
(26,676,607
)
   
(2,149,225
)
   
(28,825,832
)
Net loss
 
$
(29,657,447
)
 
$
(2,149,225
)
 
$
(31,806,672
)
Net loss per share:
                       
Basic and Diluted (as adjusted for the Reverse Stock Split)
 
$
(16.40
)
 
$
(1.19
)
 
$
(17.59
)
 
   
Nine Months Ended
 
   
September 30, 2015
 
   
As previously
             
   
reported
   
Adjustment
   
As revised
 
Revenues
 
$
30,444,581
   
$
(432,625
)
 
$
30,011,956
 
Impairment expense
   
24,717,157
     
2,027,092
     
26,744,249
 
Loss from operations
   
(30,504,220
)
   
(2,459,717
)
   
(32,963,937
)
Net loss
 
$
(31,978,604
)
 
$
(2,459,717
)
 
$
(34,438,321
)
Net loss per share:
                       
Basic and Diluted (as adjusted for the Reverse Stock Split)
 
$
(18.62
)
 
$
(1.43
)
 
$
(20.05
)

 
   
Nine Months Ended
 
   
September 30, 2015
 
   
As previously
             
   
reported
   
Adjustment
   
As revised
 
Net loss
 
$
(31,978,604
)
 
$
(2,459,717
)
 
$
(34,438,321
)
Adjustments to reconcile net loss to net cash used in operating activities:
                       
Impairment expense
   
24,717,157
     
2,027,092
     
26,744,249
 
Changes in operating assets and liabilities: deferred revenue
   
(1,522,427
)
   
432,625
     
(1,089,802
)
Cash used in operating activities
 
$
(4,206,779
)
 
$
   
$
(4,206,779
)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
 
 
2016
 
 
2015
 
Warrants to purchase common stock
 
 
514,064
 
 
 
45,314
 
Stock options
 
 
72,886
 
 
 
19,732
 
Unvested restricted stock
 
 
5,556
 
 
 
25,002
 
 
 
 
592,506
 
 
 
90,048